WHO ICTRP trial
Phase 0 clinical trial to determine capecitabine exposure in patients that have…
NL-OMON21513 · Overview of Medical Research in the Netherlands (NL-OMON) · Recruiting
Key facts
| Trial ID | NL-OMON21513 |
|---|---|
| Public title | Phase 0 clinical trial to determine capecitabine exposure in patients that have administered a new controlled release tablet of capecitabine, named ModraCape001. |
| Scientific title | Proof of principle and pharmacological phase 0 crossover study with controlled release capecitabine (ModraCape001). |
| Primary sponsor | The Netherlands Cancer Institute |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Conditions | Patients with cancer who might benefit from treatment with capecitabine, e.g. colon, breast, pancreatic and gastric cancer, ACUP. |
| Interventions | This is a proof of concept and pharmacological phase 0 crossover study whereby the new oral formulation of capecitabine, ModraCape001, will be investigated. The primary endpoint is to determine the pharmacokinetic profile of ModraCape001… |
| Registration date | Oct 3, 2012 |
| Target size | 30 |
| Secondary IDs | NL3515;NTR3647; : ;ISRCTN wordt niet meer aangevraagd. |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: